Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Recommendation of “Reduce” by Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has been assigned an average rating of “Reduce” from the nine research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and eight have issued a hold rating on the company.

Separately, Bank of America raised Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th.

Bayer Aktiengesellschaft Trading Down 1.9 %

OTCMKTS:BAYRY opened at $7.35 on Friday. Bayer Aktiengesellschaft has a 52 week low of $6.82 and a 52 week high of $11.96. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04. The company has a market cap of $28.90 billion, a PE ratio of -8.45 and a beta of 1.08. The business’s 50 day moving average is $7.75 and its two-hundred day moving average is $7.52.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, meeting the consensus estimate of $0.25. The firm had revenue of $12 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. On average, analysts predict that Bayer Aktiengesellschaft will post 1.38 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.